Palmitoyl Tetrapeptide-7
/ Synthetic palmitoylated tetrapeptide; INCI 'Palmitoyl Tetrapeptide-7'; anti-inflammatory cosmetic peptideALIAS · Rigin (trade — Sederma) · Palmitoyl Tetrapeptide-7 (INCI) · Pal-GQPR
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Sederma's Rigin (Palmitoyl Tetrapeptide-7) is marketed as an anti-inflammatory, anti-glycation cosmetic peptide. Supplier-authored ingredient dossiers cite IL-6 reduction in cytokine-stimulated fibroblast cultures. Peer-reviewed independent literature on the specific INCI is limited.
The base GQPR sequence is derived from the immunoglobulin G heavy-chain region and has been described in supplier literature as a modulator of pro-inflammatory cytokine signalling — specifically reduced IL-6 secretion in UV- or cytokine-challenged fibroblast cultures. Palmitoylation increases lipophilicity for topical delivery. The marketed claim is mitigation of low-grade chronic inflammation contributing to skin ageing.
Tier 4. Supplier-authored cell-culture and finished-product clinical data form the primary evidence base. Peer-reviewed PubMed-indexed primary literature on Palmitoyl Tetrapeptide-7 specifically is sparse.
No published independent safety database. Cosmetic INCI status implies regulatory acceptance for topical use.
Regulatory status
- FDA status:
- Not FDA-approved
The IL-6 reduction mechanism, while biologically plausible, has not been independently replicated in the peer-reviewed literature in a way that is specific to topical Palmitoyl Tetrapeptide-7 in vivo on human skin.